Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today’s newsletter has a bit of everything: peptides, China, Congress, and cancer drugs. Biotech in 2026 is never dull. Hims and Noom take peptides further into mainstream Hims & Hers and Noom are getting into the synthetic peptide business, bringing treatments marketed for muscle maintenance, intimacy, and longevity to a much larger audience — often with little evidence to support those uses. Both are already offering compounded drugs and eyeing BPC-157 and TB-500, two of six unapproved peptides covered by a new HHS policy easing enforcement against compounding pharmacies, STAT’s Sarah Todd and Katie Palmer write. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe
STAT+: Early results for Alterome’s KRAS drug for pancreas, lung and colon cancer arrive
Full Article
Original Source
Read the full article at Statnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.